Here, we identified an induction of Aurora kinase B (AURKB) in response to MEKi in BRAF-mutant thyroid cancer cells that are resistant to combined BRAF/MEK1/2 inhibition. This evidence concerns the gene MAP2K1 and thyroid gland carcinoma.